Nikolai Lorenzen

Engineering and Kinetic Profiling of a Thrombin-Activable Prodrug Antibody Targeting P-Selectin.

Antibody prodrugs represent a promising therapeutic format that provides advantages compared to conventional monoclonal antibody therapeutics. In this study, we engineered an antibody prodrug using an anti-P-selectin antibody as a model system, incorporating N-terminal heavy chai...